NASDAQ:RACA Therapeutics Acquisition (RACA) Stock Price, News & Analysis → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free RACA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$7.67▼$10.4852-Week Range N/AVolumeN/AAverage Volume105,531 shsMarket Capitalization$175.51 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisHeadlinesInsider TradesSocial MediaStock AnalysisHeadlinesInsider TradesSocial Media Get Therapeutics Acquisition alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Therapeutics Acquisition Stock (NASDAQ:RACA)Therapeutics Acquisition Corp., doing business as Research Alliance Corp. I, does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the healthcare industry in the United States. The company was incorporated in 2020 and is based in Boston, Massachusetts.Read More Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. RACA Stock News HeadlinesApril 26, 2024 | msn.comPhiladelphia-based Century Therapeutics Acquires Boston Biotechnology Firm, Clade TherapeuticsApril 7, 2024 | forbes.comHalozyme TherapeuticsMay 6, 2024 | Lear Capital (Ad)Dollar CancelledDon’t wait to protect your hard-earned savings. Top economists and billionaires are predicting that the dollar could collapse before the end of 2024.February 27, 2024 | investing.comRACA/USD - RACA US DollarJanuary 23, 2024 | morningstar.comKaruna Therapeutics Inc KRTXJanuary 9, 2024 | markets.businessinsider.comTG Therapeutics Acquires Worldwide License Agreement For Precision's Cell Therapy ProgramDecember 26, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT), AlloVir (ALVR) and Bristol-Myers Squibb (BMY)December 11, 2023 | msn.comMerger Alert: Tryp Therapeutics Signs With Australian Drug Delivery Innovator, Details HereMay 6, 2024 | Lear Capital (Ad)Dollar CancelledDon’t wait to protect your hard-earned savings. Top economists and billionaires are predicting that the dollar could collapse before the end of 2024.December 4, 2023 | news.yahoo.comRoche to acquire Carmot Therapeutics for $2.7 billionNovember 14, 2023 | markets.businessinsider.comAstria Therapeutics: Promising Clinical Data and New Licensing Agreement Bolster Buy RatingNovember 13, 2023 | markets.businessinsider.comAvenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsOctober 11, 2023 | msn.comHLTH 2023: Sidekick Health expands into prescription digital therapeutics with acquisition of aidhereOctober 9, 2023 | msn.comAmgen acquires Horizon Therapeutics for $27.8bnOctober 8, 2023 | markets.businessinsider.comAmgen Concludes Horizon Therapeutics AcquisitionOctober 6, 2023 | reuters.comAmgen completes acquisition of Horizon TherapeuticsSeptember 21, 2023 | benzinga.comBoard Member at Nektar Therapeutics Acquires Company Stock Options Worth 85,000 SharesSeptember 1, 2023 | msn.comBiopharma Giant Amgen Reaches Agreement With FTC On Acquisition of Horizon TherapeuticsSeptember 1, 2023 | msn.comFTC settles with Amgen over $27.8 billion takeover of Horizon TherapeuticsAugust 14, 2023 | finance.yahoo.comNovartis Completes Acquisition of Chinook TherapeuticsAugust 11, 2023 | technews.tmcnet.comFresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 11, 2023 | benzinga.comHDL Therapeutics to Go Public in Merger with Swiftmerge Acquisition CorpAugust 11, 2023 | marketwatch.comHDL Therapeutics to Go Public in SPAC DealAugust 9, 2023 | msn.comSPAC MedTech Acquisition shareholders approve TriSalus mergerAugust 9, 2023 | msn.comRegeneron buying small cap Decibel Therapeutics for $4 a shareJuly 31, 2023 | technews.tmcnet.comTG Therapeutics to Host Conference Call on Second Quarter 2023 Financial Results and Business UpdateJuly 28, 2023 | benzinga.comDigital Therapeutics Market to Grow Rapidly at a CAGR of 29.4% by 2030 | DataM IntelligenceSee More Headlines Receive RACA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Therapeutics Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:RACA CUSIPN/A CIKN/A Webwww.researchalliancecorp.com Phone617 778 2500FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares14,041,000Free FloatN/AMarket Cap$175.51 million OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Peter Kolchinsky Ph.D. (Age 44)Chairman & CEO Dr. Matthew Hammond M.B.A. (Age 32)Ph.D., CFO, Chief Accounting Officer, Sec. & Director Key CompetitorsOmerosNASDAQ:OMERUnion Acquisition Corp. IINASDAQ:LATNIncannex HealthcareNASDAQ:IXHLRigel PharmaceuticalsNASDAQ:RIGLCapricor TherapeuticsNASDAQ:CAPRView All Competitors This page (NASDAQ:RACA) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldAI “wealth window” is closing June 25thParadigm PressMissed NVDA? Buy this AI stock NOWChaikin AnalyticsThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldDollar CancelledLear CapitalHe Is Giving Away BitcoinCrypto Swap ProfitsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Therapeutics Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
